Abstract:
In the pharmaceutical sector, there has been a sudden acceleration in the digitalization of data over the past few years. This digitalization has come with challenges to acquire, scrutinize, and apply such particular knowledge for reaching solutions to complex clinical problems, which has ultimately motivated applications of artificial intelligence (AI) as it is able to handle huge volumes of data with augmentation of automation. AI is a system based on technology involving several modern tools and networks that mimic the intelligence of humans. Side by side, there is no threat of the physical presence of humans being completely replaced by AI. Potential applications of AI are being extended continuously in the field of pharmaceuticals, and developing pharmaceutical products from the bench to the side of the bed is imaginably provided1. AI can help in designing drugs rationally, assist in decision-making, help in the determination of the correct therapeutic management of patients, and be wisely exploited for developing drugs in the future. Eularis has developed an AI platform for analysis and making decisions known as E-VAI (Eularis Virtual Analytics Interface) that uses machine learning (ML) algorithms along with an easily usable user interface for creating analytical roadmaps. This helps executives in marketing allocate resources for maximum share gain in the market and reverse poor sales
